/Companies

Reset Therapeutics

South San Francisco, US · Delaware corporation · 2 known investors

Find your way into Reset Therapeutics

Sign up to see every warm intro you have to Reset Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Reset Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Founders & leadership

SK
Shuichi KurosakiExecutive
PH
Paul HumphriesExecutive
RB
Ross BersotExecutive
SK
Steve KayNamed on SEC filing
PS
Peter SchultzNamed on SEC filing

Board

FB
Frederick B CravesBoard directorGeneral Partner at Bay City Capital GF Xinde International Life Sciences USD
HH
Hoyoung HuhBoard director

Investors · 2

Reported raises · per SEC filings

Form D private placements

$47.9M disclosed across 5 rounds · 2014–2022

▶$1.6MraisedJan 2022 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Blair JacksonDirector
  • Steve KayDirector
  • Frederick B CravesDirector
  • Shu KurosakiExecutive Officer
  • Glenn BatchelderExecutive Officer, Director
Offering amount
$3M
Amount sold
$1.6M
First sale
Jan 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedOct 2019 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Frederick B CravesDirector
  • Steve KayDirector
  • Shuichi KurosakiExecutive Officer
  • Glenn BatchelderExecutive Officer, Director
  • Blair JacksonDirector
Offering amount
$6M
Amount sold
$6M
First sale
Sep 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedJun 2018 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Blair JacksonDirector
  • Glenn BatchelderDirector
  • Frederick B CravesDirector
  • Steve KayDirector
  • Shuichi KurosakiExecutive Officer
Offering amount
$1.5M
Amount sold
$1.5M
First sale
Jun 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$29.7MraisedFeb 2016 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Hoyoung HuhDirector
  • Ross BersotExecutive Officer, Director
  • Shuichi KurosakiExecutive Officer
  • Frederick B CravesDirector
  • Steve KayDirector
  • Peter SchultzDirector
  • Paul HumphriesExecutive Officer
Offering amount
$47.2M
Amount sold
$29.7M
First sale
Feb 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.1MraisedOct 2015 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Shuichi KurosakiExecutive Officer
  • Paul HumphriesExecutive Officer
  • Steve KayDirector
  • Frederick B CravesDirector
  • Hoyoung HuhDirector
  • Peter SchultzDirector
  • Ross BersotExecutive Officer, Director
Offering amount
$12M
Amount sold
$9.1M
First sale
Jun 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who are Reset Therapeutics's investors?
Reset Therapeutics's investors include Bay City Capital GF Xinde International Life Sciences USD, Goldcrest Capital.
How much funding has Reset Therapeutics raised?
Reset Therapeutics has disclosed $47.9M raised across 5 rounds.
Where is Reset Therapeutics headquartered?
Reset Therapeutics is headquartered in South San Francisco, US.